Philogen SpA (MIL:PHIL) 5-Year Yield-on-Cost %: 2.74 (As of Jul. 12, 2026)


MIL:PHIL Philogen SpA MIL:PHIL
61 GF Score
Price €25.55
GF Value €229.03
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Philogen SpA 5-Year Yield-on-Cost %?

Philogen SpA MIL:PHIL +0.39% 61 5-Year Yield-on-Cost % is 2.74 as of Jul. 12, 2026. GuruFocus rates MIL:PHIL with a GF Score™ of 61/100 and a GF Value™ of €229.03 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 153 Biotechnology companies, Philogen SpA ranks better than 62.75% on this metric.

Philogen SpA's yield on cost for the quarter that ended in Dec. 2025 was 2.74.


The historical rank and industry rank for Philogen SpA's 5-Year Yield-on-Cost % or its related term are showing as below:

MIL:PHIL' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0   Med: 0   Max: 2.74
Current: 2.74


During the past 6 years, Philogen SpA's highest Yield on Cost was 2.74. The lowest was 0.00. And the median was 0.00.


MIL:PHIL's 5-Year Yield-on-Cost % is ranked better than
62.75% of 153 companies
in the Biotechnology industry
Industry Median: 1.7 vs MIL:PHIL: 2.74

Philogen SpA  (MIL:PHIL) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Philogen SpA 5-Year Yield-on-Cost % Related Terms


MIL:PHIL vs VRTX, REGN, ALNY: 5-Year Yield-on-Cost % Comparison

For the Biotechnology subindustry, Philogen SpA's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Philogen SpA 5-Year Yield-on-Cost % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Philogen SpA's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Philogen SpA's 5-Year Yield-on-Cost % falls into.


MIL:PHIL
61GF Score
Philogen SpA MIL:PHIL
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Philogen SpA 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Philogen SpA is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 2.74 mean?
Philogen SpA (MIL:PHIL) has a 5-Year Yield-on-Cost % of 2.74 as of Jul. 12, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Philogen SpA and its competitors. According to the industry distribution chart, Philogen SpA ranks #57 out of 153 companies in the Biotechnology industry, placing it in the top 37.3%.
Is Philogen SpA's 5-Year Yield-on-Cost % too high?
Philogen SpA's current 5-Year Yield-on-Cost % is 2.74. The Biotechnology industry median 5-Year Yield-on-Cost % is 1.70. Philogen SpA's value of 2.74 is 61.2% above this industry median. Based on the distribution chart, Philogen SpA ranks #57 out of 153 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Philogen SpA has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Philogen SpA's 5-Year Yield-on-Cost % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Philogen SpA ranks #57 out of 153 companies for 5-Year Yield-on-Cost %. This puts Philogen SpA in the upper half of its industry. The industry median 5-Year Yield-on-Cost % is 1.70. Philogen SpA's value of 2.74 is 61.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.70, based on 153 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Philogen SpA's current 5-Year Yield-on-Cost % of 2.74 is 61.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Philogen SpA and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Philogen SpA's current 5-Year Yield-on-Cost % is 2.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Philogen SpA stock overvalued right now?
Based on GuruFocus' analysis, Philogen SpA (MIL:PHIL) is currently considered Possible Value Trap. The stock's GF Value™ is €229.03, compared to a current price of €25.55 — trading 88.8% below its estimated fair value. The current 5-Year Yield-on-Cost % is 2.74 and 61.2% above the Biotechnology industry median of 1.70. Philogen SpA's overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Philogen SpA (MIL:PHIL), the current 5-Year Yield-on-Cost % is 2.74 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Philogen SpA (MIL:PHIL) Overvalued in 2026?

Based on GuruFocus' analysis, Philogen SpA stock appears to be undervalued. The current stock price of €25.55 is trading 88.8% below its estimated GF Value™ of €229.03. GuruFocus considers Philogen SpA to be Possible Value Trap.

Key valuation signals for MIL:PHIL:

  • 5-Year Yield-on-Cost %: 2.74
  • GF Value™: €229.03 vs. price of €25.55 (88.8% below fair value)
  • GF Score™: 61/100 with 4 warning signs
  • Industry Position: 61.2% above the Biotechnology median (#57 of 153)

No single metric tells the full story. See the MIL:PHIL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Philogen SpA Business Description

Other Exchanges 78Q:Germany
Address Piazza La Lizza No. 7, Siena, ITA, 53100
Philogen SpA is a biotechnology company engaged in the research and development of antibody-based therapeutics for the treatment of cancer and chronic inflammatory diseases. The company's pipeline includes products such as Nidlegy, Fibromun, Darleukin, and Dekavil, targeting oncology and other serious conditions. Geographically, the company operates in the European Union, Switzerland, and the United States of America.
61GF Score

Get the complete analysis for MIL:PHIL

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€25.55
Price
€229.03
GF Value